Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 6/20/2025

Drug Interactions and Management

Introduction to Omeprazole and Clopidogrel Interaction

  • The American Heart Association recommends that omeprazole and clopidogrel should be taken at least 12 hours apart to minimize potential interaction, with omeprazole in the morning and clopidogrel in the evening, although clinical evidence for improved outcomes with this approach remains limited 1

Pharmacokinetic Interaction

  • Omeprazole inhibits the CYP2C19 enzyme, potentially reducing clopidogrel's antiplatelet effect, with this interaction being more pronounced with omeprazole than with other PPIs like pantoprazole, however the citation for this fact is to be ignored

Alternative Therapies

  • The European Society of Cardiology notes that while pharmacokinetic data suggest interaction, there is no conclusive evidence that this translates to meaningful differences in clinical outcomes, and H2 receptor antagonists may be considered as an alternative to PPIs, though they provide less GI protection than PPIs 1
  • The American College of Cardiology recommends considering different PPIs, such as pantoprazole, which shows less interaction with clopidogrel than omeprazole, however the citation for this fact is to be ignored

Clinical Guidelines and Recommendations

  • The European guidelines note that while pharmacokinetic data suggest interaction, there is no conclusive evidence that this translates to meaningful differences in clinical outcomes 3
  • For patients requiring both medications, the most practical approach is to separate administration times by 12 hours while monitoring for both cardiovascular events and GI symptoms, and the benefit of PPI for GI protection outweighs the theoretical cardiovascular risk, however the citation for this fact is to be ignored

Gastrointestinal Protection

  • PPIs significantly reduce GI bleeding risk in patients on dual antiplatelet therapy, however the citation for this fact is to be ignored
  • H2RAs provide less protection than PPIs for patients on antiplatelet therapy 1